Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O’day Sells 10,000 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $126.54, for a total value of $1,265,400.00. Following the completion of the transaction, the chief executive officer owned 571,203 shares of the company’s stock, valued at $72,280,027.62. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Daniel Patrick O’day also recently made the following trade(s):

• On Tuesday, October 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00.
• On Monday, September 29th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00.

Gilead Sciences Stock Down 1.2%

Shares of NASDAQ:GILD opened at $124.33 on Tuesday. The company has a market capitalization of $154.25 billion, a price-to-earnings ratio of 24.77, a PEG ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 12-month low of $88.57 and a 12-month high of $128.70. The business has a 50-day moving average price of $120.11 and a 200 day moving average price of $114.87. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on GILD shares. Needham & Company LLC boosted their target price on Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Morgan Stanley boosted their price objective on Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Citigroup raised their target price on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a research report on Friday, October 31st. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $130.65.

Hedge Funds Weigh In On Gilead Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC grew its holdings in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC acquired a new position in Gilead Sciences in the fourth quarter valued at $215,000. XTX Topco Ltd raised its stake in Gilead Sciences by 76.8% during the 1st quarter. XTX Topco Ltd now owns 9,156 shares of the biopharmaceutical company’s stock valued at $1,026,000 after acquiring an additional 3,976 shares during the last quarter. Baker Avenue Asset Management LP purchased a new stake in shares of Gilead Sciences during the first quarter worth approximately $279,000. Finally, PNC Financial Services Group Inc. raised its stake in shares of Gilead Sciences by 3.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 408,113 shares of the biopharmaceutical company’s stock worth $45,729,000 after buying an additional 14,312 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.